Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Amgen announced new Repatha trial results from its landmark Phase 3 VESALIUS-CV study. The data showed Repatha (evolocumab) cut the risk of a first heart attack by 36%. It also reduced the risk of ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...

Praluent and Repatha both lower bad cholesterol in certain people but have different approved uses and age limits. These drugs can have side effects like cold-like symptoms and injection site ...

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that regulates LDL cholesterol levels in the bloodstream. The medication is approved in more than 74 countries for reducing ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab will be made available to eligible patients via a new direct-to-consumer program. The PCSK9 inhibitor ...

Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable at a discounted cash price through Amgen's new direct-to-patient program, ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $160.7 billion, announced Thursday that its Phase 3 VESALIUS-CV clinical ...

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...

Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...